| pubmed-article:16458505 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16458505 | lifeskim:mentions | umls-concept:C0162714 | lld:lifeskim |
| pubmed-article:16458505 | lifeskim:mentions | umls-concept:C0205349 | lld:lifeskim |
| pubmed-article:16458505 | lifeskim:mentions | umls-concept:C1880355 | lld:lifeskim |
| pubmed-article:16458505 | lifeskim:mentions | umls-concept:C1530885 | lld:lifeskim |
| pubmed-article:16458505 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:16458505 | pubmed:dateCreated | 2006-2-27 | lld:pubmed |
| pubmed-article:16458505 | pubmed:abstractText | A novel series of P1 modified HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and protease inhibitor-resistant viruses. Optimization of the P1 moiety resulted in compounds with femtomolar enzyme activities and cellular antiviral activities in the low nanomolar range culminating in the identification of clinical candidate GW0385. | lld:pubmed |
| pubmed-article:16458505 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16458505 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16458505 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16458505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16458505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16458505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16458505 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16458505 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16458505 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:HanlonMary... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:FurfineEric... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:ReynoldsDavid... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:KaldorIstvanI | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:SpaltensteinA... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:HazenRichard... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:McLeanEd WEW | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:TurnerElizabe... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:SherrillRonal... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:HaleMichael... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:XuRobert XRX | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:MillerJohn... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:AndrewsC... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:SammondDougla... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:BriegerMichae... | lld:pubmed |
| pubmed-article:16458505 | pubmed:author | pubmed-author:TungRogerR | lld:pubmed |
| pubmed-article:16458505 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16458505 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16458505 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16458505 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16458505 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16458505 | pubmed:pagination | 1788-94 | lld:pubmed |
| pubmed-article:16458505 | pubmed:meshHeading | pubmed-meshheading:16458505... | lld:pubmed |
| pubmed-article:16458505 | pubmed:meshHeading | pubmed-meshheading:16458505... | lld:pubmed |
| pubmed-article:16458505 | pubmed:meshHeading | pubmed-meshheading:16458505... | lld:pubmed |
| pubmed-article:16458505 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16458505 | pubmed:articleTitle | Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. | lld:pubmed |
| pubmed-article:16458505 | pubmed:affiliation | GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. john.6.miller@gsk.com | lld:pubmed |
| pubmed-article:16458505 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16458505 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16458505 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16458505 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16458505 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16458505 | lld:pubmed |
